PMID- 14719133
OWN - NLM
STAT- MEDLINE
DCOM- 20040308
LR  - 20220318
IS  - 1107-3756 (Print)
IS  - 1107-3756 (Linking)
VI  - 13
IP  - 2
DP  - 2004 Feb
TI  - Expression of IL-18 in patients with head and neck squamous cell carcinoma.
PG  - 267-72
AB  - Interleukin-18 (IL-18), a recently described cytokine secreted mainly by 
      macrophages, stimulates interferon-gamma (IFN-gamma) production by natural killer 
      cells and T cells. The purpose of this study was to determine tissue expression 
      and serum levels of IL-18 in head and neck squamous cell carcinoma (HNSCC) and to 
      evaluate ethanol and endotoxin-driven cytokine secretion. In 24 patients with 
      primary HNSCC and 28 healthy controls, PBMC were isolated and incubated with 50 
      mM ethanol, LPS (doses 25 ng/ml, 250 ng/ml, 2500 ng/ml) and both agents for 24 h. 
      Levels of IL-18 in serum, and cell supernatants were analysed by capture ELISA, 
      IL-18 tissue level by immunoblotting. Serum levels of IL-8, IL-10 and IL-12, 
      IFN-gamma, and endotoxin plasma levels were also determined. Statistical analysis 
      involved Welch t-test and Page's test for trend. The majority of patients with 
      HNSCC had high concentrations of serum IL-18. The level of IL-18 in the sera of 
      these patients had a mean level of 271.7 pg/ml, while the mean IL-18 serum level 
      in healthy controls was 174,0 pg/ml (p<0.001). Levels of IL-10 and IL-12, 
      IFN-gamma were not increased in patients. Endotoxin was not detectable in either 
      group. LPS stimulated dose-dependently IL-18 secretion from PBMC of patients and 
      controls in vitro (p<0.05). Incubation with ethanol alone did not affect basal 
      IL-18 secretion, but ethanol reduced LPS-stimulated IL-18 secretion compared to 
      LPS stimulation alone. The mRNA expression of IL-18 in unstimulated PBMC and the 
      response of PBMC to ethanol and LPS was similar in patients and controls. Our 
      data on elevated serum levels of IL-18 in the majority of HNSCC cancer patients, 
      irrespective of its biological activity, suggest that serum IL-18 might be a 
      candidate for a new marker for HNSCC. The pathways for IL-18 production and its 
      mechanisms of action in patients with HNSCC remain to be determined. 
      Understanding of the immunological pathways might offer new therapeutic options 
      in head and neck cancer in the future.
FAU - Riedel, Frank
AU  - Riedel F
AD  - Universitats-HNO-Klinik, Theodor-Kutzer-Ufer, D-68135 Mannheim, Germany. 
      frank.riedel@hno.ma.uni-heidelberg.de
FAU - Adam, Sylvie
AU  - Adam S
FAU - Feick, Peter
AU  - Feick P
FAU - Haas, Stephan
AU  - Haas S
FAU - Gotte, Karl
AU  - Gotte K
FAU - Hormann, Karl
AU  - Hormann K
CN  - Mannheim Alcohol Study Group
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Int J Mol Med
JT  - International journal of molecular medicine
JID - 9810955
RN  - 0 (Interleukin-18)
SB  - IM
MH  - Carcinoma, Squamous Cell/*metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Head and Neck Neoplasms/*metabolism
MH  - Humans
MH  - Interleukin-18/biosynthesis/blood/*genetics
MH  - Leukocytes, Mononuclear/metabolism
MH  - Male
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2004/01/14 05:00
MHDA- 2004/03/09 05:00
CRDT- 2004/01/14 05:00
PHST- 2004/01/14 05:00 [pubmed]
PHST- 2004/03/09 05:00 [medline]
PHST- 2004/01/14 05:00 [entrez]
PST - ppublish
SO  - Int J Mol Med. 2004 Feb;13(2):267-72.